Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISLEND-2 weekly oral islatravir + lenacapavir switch study in virologically suppressed adults with HIV-1
NL-OMON59437Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Human immunodeficiency virus infection type 1 comparing Weekly oral islatravir + lenacapavir switch arm with Continue standard of care arm (2 arms). Primary endpoint: Proportion of participants with HIV-1 RNA >=50 copies/mL at Week 48. Started Mar 2025; status: active, not recruiting.
02
Drugs
islatravirlenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON59437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59437.